Home > Oncology > ASCO 2019 > Gastrointestinal Cancers > KEYNOTE-062: Pembrolizumab Combination Fails to Improve Survival in Gastric/GEJ Cancer

KEYNOTE-062: Pembrolizumab Combination Fails to Improve Survival in Gastric/GEJ Cancer

Presented By
Dr Josep Tabernero,Vall d’Hebron University Hospital, Spain
Conference
ASCO 2019
Trial
Phase 3, KEYNOTE-062

Medical writer: Muriel Cunningham

Pembrolizumab plus chemotherapy failed to prolong overall survival (OS) and progression-free survival (PFS) among patients with PD-L1–positive gastric and gastroesophageal cancers, according to results from the phase III KEYNOTE-062 trial (Abstract LBA4007). Pembrolizumab monotherapy improved OS among patients with high PD-L1 expression but not PFS.

The objective of the KEYNOTE-062 trial (NCT02494583) was to determine the safety and efficacy of first-line treatment with pembrolizumab with and without chemotherapy in patients with gastric or gastroesophageal cancer. This study was conducted in patients with HER2-negative, advanced gastric or gastroesophageal cancer who had a PD-L1 combined positive score (CPS) of 1 or higher. Josep Tabernero, MD, PhD, of Vall d’Hebron University Hospital, Spain, presented the study results.

Patients who met eligibility criteria were randomly selected 1:1:1 to one of the following thre...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on